Global News

Warnex completes sale of bioanalytical services to CRO Biotrial

Monday, December 17, 2012 11:06 AM

Warnex, a life sciences company, has successfully completed the sale of its bioanalytical services division to Biotrial Research, a privately-owned CRO headquartered in France.

More... »

Thiel Foundation’s Breakout Labs awards three new grants

Friday, December 14, 2012 02:03 PM

The Thiel Foundation has announced three new grants awarded to AVEtec, General Genomics, and Siva Therapeutics through Breakout Labs, its revolving fund to promote innovation in science and technology.

More... »

Fresenius to discontinue biotech subsidiary

Friday, December 14, 2012 01:27 PM

Fresenius, a health care group with international operations, has decided to discontinue its subsidiary Fresenius Biotech. Instead, the company will focus on its four established business segments Fresenius Medical Care, Fresenius Kabi, Fresenius Helios and Fresenius Vamed, which offer significant growth opportunities.

More... »

Bayer submits NDA for radium Ra 223 dichloride for castration-resistant prostate cancer

Friday, December 14, 2012 12:07 PM

Bayer HealthCare has submitted a New Drug Application (NDA) to the FDA seeking approval for radium Ra 223 dichloride (radium-223), a fast tracked investigational compound for the treatment of castration-resistant prostate cancer (CRPC) patients with bone metastases.

More... »

Lilly discontinues 1 of 3 phase III rheumatoid arthritis registration studies for tabalumab

Friday, December 14, 2012 11:40 AM

Global pharmaceutical company Eli Lilly is halting one of three phase III rheumatoid arthritis (RA) registration studies of tabalumab, an anti-BAFF monoclonal antibody, due to insufficient efficacy.

More... »

Biocartis completes $44.5M series D funding

Friday, December 14, 2012 11:12 AM

Biocartis, a molecular diagnostics company developing and commercializing high quality, easy to use platforms and clinically relevant oncology assays, has completed a $44.5 million Series D equity funding entirely backed by existing investors.

More... »

Eisai, UCL form drug discovery alliance for neurological diseases

Friday, December 14, 2012 10:43 AM

Eisai, a pharmaceutical company based in Toyko, and University College London (UCL) have entered into a new agreement to establish a major drug discovery and development collaboration investigating new ways of treating neurological diseases such as Alzheimer’s disease, Parkinson’s disease and other related disorders.

More... »

Insero Health completes phase I trial in drug resistant epilepsy

Thursday, December 13, 2012 08:00 AM

Insero Health, a clinical-stage company that develops small molecule therapies derived from natural products to treat neurological diseases, has completed a phase Ib trial of its lead compound INS001 in patients with drug-resistant epilepsy. 

More... »

GSK, Vodafone to help increase childhood vaccination in Mozambique

Wednesday, December 12, 2012 11:44 AM

Global healthcare company GlaxoSmithKline (GSK) has formed a partnership with Vodafone, one of the world's largest mobile communications companies, to harness innovative mobile technology to help vaccinate more children against common infectious diseases in Africa.

More... »

Chiltern welcomes Cedric Burg and James Gunter

Wednesday, December 12, 2012 11:29 AM

Chiltern International, a global CRO, has appointed Dr. Cedric Burg and James Gunter to their team.

More... »